Advertisement

Journal of General Internal Medicine

, Volume 11, Issue 12, pp 768–770 | Cite as

Should we just let the anticoagulation service do it?

The conundrum of anticoagulation for atrial fibrillation
  • David B. Matchar
  • Gregory P. Samsa
  • Stuart J. Cohen
Editorials

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Antani MR, Beyth RJ, Covinsky KE, et al. Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation. J Gen Intern Med. 1996;11:713–20.PubMedGoogle Scholar
  2. 2.
    Beyth RJ, Antani MR, Covinsky KE, et al. Why isn’t warfarin prescribed to patients with nonrheumatic atrial fibrillation? J Gen Intern Med. 1996;11:721–8.PubMedGoogle Scholar
  3. 3.
    Petersen P, Boysen G, Godtfredsen G, Andersen ED, Andersen B. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study. Lancet. 1989;1:175–9.PubMedCrossRefGoogle Scholar
  4. 4.
    European Atrial Fibrillation Trial Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic or minor stroke. Lancet. 1993;342:1256–62.Google Scholar
  5. 5.
    Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. N Engl J Med. 1990;323:1505–11.CrossRefGoogle Scholar
  6. 6.
    Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: Final results. Circulation. 1991;84:527–39.Google Scholar
  7. 7.
    Connolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner CH. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18:349–55.PubMedCrossRefGoogle Scholar
  8. 8.
    Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation. N Engl J Med. 1992;327:1406–12.PubMedCrossRefGoogle Scholar
  9. 9.
    Laupacis A, Albers G, Dalen J, Dunn M, Feinberg W, Jacobson A. Antithrombotic therapy in atrial fibrillation. Chest. 1995;108:352S-9S.PubMedGoogle Scholar
  10. 10.
    Matchar DB, McCrory D, Barnett H, Feussner JR. Medical treatment for stroke prevention. Ann Intern Med. 1994;121:41–53.PubMedGoogle Scholar
  11. 11.
    Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM, for the CHS Collaborative Research Group. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994;74:236–41.PubMedCrossRefGoogle Scholar
  12. 12.
    Antani MR, Beyth RJ, Anderson PA, Katirji B, Miller DG, Moir W, O’Brien T, Landefeld CS. Warfarin to prevent atrial fibrillation-related stroke: frequency and appropriateness of use in urban practice. J Gen Intern Med. 1994;9(Suppl 2):24a.Google Scholar
  13. 13.
    AHCPR, Dupont Merck and Duke to collaborate on education trial for stroke prevention therapy. The Blue Sheet. 1996 May 5;2–4.Google Scholar
  14. 14.
    Caro JJ, Groome PA, Flegel KM. Atrial fibrillation and anticoagulation: from randomized trials to practice. Lancet. 1993;154:1443–8.Google Scholar
  15. 15.
    Eckman MH, Levine JH, Pauker SG. Making decisions about anti-thrombotic therapy in heart disease. Chest. 1995;108:457s-70s.PubMedGoogle Scholar
  16. 16.
    Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med. 1987;147:1561–4.PubMedCrossRefGoogle Scholar
  17. 17.
    Matchar DB, Duncan PW. Cost of stroke. Stroke: Clin Updates. 1994;V(3):9–12.Google Scholar
  18. 18.
    Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral Anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1995;108:231s-46s.PubMedGoogle Scholar
  19. 19.
    Albers GW. Atrial fibrillation and stroke: three new studies, three remaining questions. Arch Intern Med. 1994;154:1443–8.PubMedCrossRefGoogle Scholar
  20. 20.
    The European Atrial Fibrillation Trial Study Group. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995;333:5–10.CrossRefGoogle Scholar
  21. 21.
    Hylek HM, Skates SJ, Sheehan MA, Singer DE. An analysis of lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996;335:540–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Finn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann Intern Med. 1996;124:970–9.Google Scholar
  23. 23.
    Chang HJ, Bell JR, Deroo DB, Kirk JW, Wasson JH. Physician variation in anticoagulating patients with atrial fibrillation. Arch Intern Med. 1990;150:81–4.CrossRefGoogle Scholar
  24. 24.
    Kutner M, Nixon G. Silverstone F. Physicians’ attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation. Arch Intern Med. 1991;151:1950–3.PubMedCrossRefGoogle Scholar
  25. 25.
    McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett ELC. Physician attitudes about anticoagulation for nonvalvular atrial fibrillation in the elderly. Arch Intern Med. 1995;155:277–81.PubMedCrossRefGoogle Scholar
  26. 26.
    Goldstein LB, Bonito AJ, Matchar DB, Duncan DW, Samsa GP. U.S. national survey of physician practices for the secondary and tertiary prevention of ischemic stroke: carotid endarterectomy. Stroke. 1996;27(5):801–6.PubMedGoogle Scholar
  27. 27.
    Lancaster TR, Singer DE, Sheehan MA, Oertel LB, Maraventano SE, Hughes RA, Kistler JP, for the Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The impact of long-term warfarin therapy: evidence from a randomized trial. Arch Intern Med. 1991;151:1944–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Gottlieb LK, Salem-Schatz S. Anticoagulation in atrial fibrillation: does efficacy in clinical trials translate into effectiveness in practice? Arch Intern Med. 1994;154:1945–53.PubMedCrossRefGoogle Scholar
  29. 29.
    Feinstein AR. The chagrin factor and qualitative decision analysis. Arch Intern Med. 1985;45:1257–9.CrossRefGoogle Scholar
  30. 30.
    Errichetti AM, Holden A, Ansell J. Management of oral anticoagulant therapy: experience with an anticoagulation clinic. Arch Intern Med. 1984;144:1966–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Charney R, Leddomado E, Rose DN, Fuster V. Anticoagulation services and the monitoring of anticoagulant therapy. Intl J Cardiol. 1988;18:197–206.CrossRefGoogle Scholar
  32. 32.
    Davis FB, Estruch MT, Samson-Corvera EB, Voigt GC, Tobin JD. Management of anticoagulation in outpatients. Arch Intern Med. 1977;137:197–202.PubMedCrossRefGoogle Scholar
  33. 33.
    Ellis RF, Stephens MA, Sharp GB. Evaluation of a pharmacy-managed warfarin monitoring service to coordinate inpatient and outpatient therapy. Am J Hosp Pharm. 1992;49:387–94.PubMedGoogle Scholar
  34. 34.
    Garabedian-Ruffalo SM, Graym D, Sax MJ, Ruffalo RL. Retrospective evaluation of a pharmacist-managed anticoagulation service. Am J Hosp Pharm. 1985;42:304–8.PubMedGoogle Scholar
  35. 35.
    Landefeld CS, Anderson PA. Guideline-based consultation to prevent anticoagulant-related bleeding: a randomized, controlled trial in a teaching hospital. Ann Intern Med. 1992;116:829–37.PubMedGoogle Scholar
  36. 36.
    Kumar S, Haigh JRM, Rhodes LE, Peaker S, Davies JA, Roberts BE, Freely MP. Poor compliance is a major factor in unstable outpatient control of anticoagulant therapy. Thrombosis and Haemostasis. 1989;62(2):729–32.PubMedGoogle Scholar
  37. 37.
    Bussey HI, Rospond RM, Quandt CM, Clark GM. The safety and effectiveness of long-term warfarin therapy in an anticoagulation clinic. Pharmacotherapy. 1989;9(4):214–9.PubMedGoogle Scholar
  38. 38.
    Gray DR. Garabedian-Ruffalo SM, Chretien SD. Cost-justification of a clinical pharmacist-managed anticoagulation clinic. Drug Intelligence and Clinical Pharmacy. 1985;19:575–80.PubMedGoogle Scholar
  39. 39.
    Seabrook GR, Karp D, Schmitt DD, Bandyk DF. An outpatient anticoagulation protocol managed by a vascular nurse-clinician. Am J Surgery. 1990;160:501–5.CrossRefGoogle Scholar
  40. 40.
    Hall J, Radley AS. A role for community pharmacists in the control of anticoagulant therapy. The Pharmaceutical Journal. 1994;252:230–2.Google Scholar
  41. 41.
    Radley AS, Hall J. The establishment and evaluation of a pharmacist-developed anticoagulant therapy. The Pharmaceutical Journal. 1994;252:91–2.Google Scholar
  42. 42.
    Kornblit P, Senderoff J, Davis-Erickson M, Zenk J. Anticoagulation therapy: patient management and evaluation of an outpatient clinic. Nurse Practitioner. 1990;15:21–32.PubMedGoogle Scholar
  43. 43.
    van der Meer FMJ, Rosnedaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med. 1993;153:1557–62.PubMedCrossRefGoogle Scholar
  44. 44.
    Besselaar AM, Meer FJ, Gerrits-Drabbe CW. Therapeutic control of oral anticoagulant treatment in the Netherlands. Am J Clin Pathol. 1988;90:685–90.PubMedGoogle Scholar
  45. 45.
    Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 108;1995;231s-46s.PubMedGoogle Scholar

Copyright information

© Blackwell Science, Inc. 1996

Authors and Affiliations

  • David B. Matchar
    • 1
    • 2
  • Gregory P. Samsa
    • 1
    • 2
  • Stuart J. Cohen
    • 1
    • 2
  1. 1.Duke UniversityDurham
  2. 2.Bowman Gray School of MedicineWake Forest UniversityWinston-Salem

Personalised recommendations